Colon Cancer

Oncology·MeSH: Colonic Neoplasms

Prevalence

135.0 / 100K

Incidence

36.0 / 100K/yr

21 drugs in development·8 companies·24 clinical trials

Drug Pipeline by Phase

Phase 3(12)

Drug	Company
Calcium Folinate	Merus N.V. (MRUS)
Chemotherapy	Crinetics Pharmaceuticals, Inc. (CRNX)
FOLFIRI Protocol	IGM Biosciences, Inc. (IGMS)
Fruquintinib	IGM Biosciences, Inc. (IGMS)
Mitomycin	KYNTRA BIO INC. (KYNB)
Neoadjuvant chemotherapy	Crinetics Pharmaceuticals, Inc. (CRNX)
Panitumumab	IGM Biosciences, Inc. (IGMS)
Pertuzumab	IGM Biosciences, Inc. (IGMS)
standard management	Crinetics Pharmaceuticals, Inc. (CRNX)
Temozolomide	IGM Biosciences, Inc. (IGMS)
timing to initiate the adjuvant FOLFOX chemotherapy	BridgeBio Oncology Therapeutics, Inc. (BBOT)
treatment adaptation guided by ctDNA variation	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 2(2)

Drug	Company
Dostarlimab	Crinetics Pharmaceuticals, Inc. (CRNX)
lsta1	LISATA THERAPEUTICS, INC. (LSTA)

Phase 1(3)

Early Phase 1(1)

Drug	Company
Curcumin	Merus N.V. (MRUS)

Phase 4(3)

BioSniper tracks 21 drugs in development for Colon Cancer across 8 companies.

There are 24 clinical trials targeting Colon Cancer tracked by BioSniper.

The estimated prevalence of Colon Cancer is approximately 135.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.